NCT06562647 2026-02-13SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid TumorsCell Origin Biotech (Hangzhou) Co., Ltd.Phase NA Recruiting2 enrolled